Brief: Erytech Provides Update On The Trybeca-1 Phase 3 Clinical Trial Of Eryaspase In Second Line Pancreatic Cancer

Phaxiam Therapeutics SA

28/04/2020 22:23

April 28 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL
TRIAL
OF ERYASPASE IN SECOND LINE PANCREATIC CANCER
    * ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL
TRIAL
OF ERYASPASE IN SECOND LINE PANCREATIC CANCER
    * ERYTECH PHARMA SA - TRIAL TO CONTINUE AS PLANNED AFTER
THIRD
SAFETY REVIEW BY INDEPENDENT DATA MONITORING COMMITTEE
    * ERYTECH PHARMA SA - INTERIM SUPERIORITY ANALYSIS EXPECTED
AROUND
YEAR-END; FINAL ANALYSIS IN SECOND HALF OF 2021
    * ERYTECH PHARMA SA - NO SAFETY ISSUES WERE IDENTIFIED AND
IDMC
RECOMMENDED TO CONTINUE TRIAL AS PLANNED
    * ERYTECH PHARMA SA - TO DATE, MORE THAN 75% OF
APPROXIMATELY 500
PATIENTS TO BE ENROLLED IN TRIAL HAVE BEEN RANDOMIZED

Source text for Eikon:  ID:nGNXbBzHZ3 
Further company coverage:  ERYP.PA 

 ((Briefs@thomsonreuters.com;))